Published 3 days ago • loading... • Updated 3 days ago

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

Brii Biosciences Limited presented a cross-study analysis at the 35th Annual Meeting of the Asian Pacific Association for the Study of the Liver in Istanbul, Turkey, from April 22-25, led by Professor Jidong Jia of the Beijing Friendship Hospital.
The analysis evaluated post-treatment HBsAg rebound in participants with chronic hepatitis B virus infection who achieved HBsAg loss in the Phase 2 ENSURE study or the Phase 2 BRII-179-002 study.
Post-Treatment HBsAg rebound occurred in 43.6% of participants, although 75.0% of rebounds remained below 10 IU/mL and HBV DNA rebound was infrequent without significant alanine aminotransferase elevations.
Notably, shorter nucleoside reverse transcriptase inhibitor consolidation periods of 12 to 20 weeks were not associated with higher HBsAg rebound rates compared to 24 weeks, suggesting feasibility for shortening treatment.
David Margolis, Chief Medical Officer of Brii Bio, stated the company is encouraged by evidence that novel therapeutic combinations achieve rapid HBsAg loss and durable immunological control supporting future HBV cure strategies.

Insights by Ground AI

14 Articles

The Daily News - Jacksonville, NC

+13 Reposted by 13 other sources

Lean Right

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year